药物耐药性和胆囊癌的新疗法
Yuxin Sun1, Xiaoxuan Li2, Haihong Cheng1
1Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
胆囊癌 (GBC) 化学抵抗阻碍了治疗. 本综述探讨了过去十年的GBC分子化学抵抗机制,为这种攻击性癌症寻找新的治疗点.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
背景情况:
- 胆囊癌 (GBC) 是一种具有攻击性的恶性瘤,由于诊断挑战,预后不佳.
- 化疗是不可切割的GBC的主要治疗方法,但化疗抵抗限制了其有效性.
- 了解GBC化学抵抗机制对于改善患者的治疗结果至关重要.
研究的目的:
- 在过去十年中,审查GBC中化疗耐药性的分子机制.
- 确定GBC治疗的潜在治疗和实验目标.
主要方法:
- 关于过去10年发表的研究的文献综述.
- 专注于胆囊癌中基因抵抗的分子机制.
主要成果:
- 在GBC中,化学抵抗是由复杂的分子变化驱动的.
- 讨论了导致耐药性的关键途径和遗传突变.
- 该综述综合了关于GBC化学抵抗的当前知识.
结论:
- 阐明GBC化学抵抗机制对于开发有效疗法至关重要.
- 已识别的分子标为新的治疗策略提供了潜力.
- 需要进一步的研究来将这些发现转化为临床实践.
更多相关视频
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Tumor Immunotherapy
